Literature DB >> 22644963

Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.

Wolfgang Haas1, Lynne S Gearinger, Christine K Hesje, Christine M Sanfilippo, Timothy W Morris.   

Abstract

INTRODUCTION: Bacterial conjunctivitis is a contagious infection of the surface of the eye usually treated empirically with topical antibiotics. Since the etiologic agent is rarely identified, it is important to monitor which bacteria cause conjunctivitis and determine their antibacterial resistance profiles.
METHODS: A total of 496 bacterial samples were isolated during a randomized, double-masked, vehicle-controlled, parallel-group study conducted in the United States with besifloxacin ophthalmic suspension 0.6% dosed twice daily. Species were determined by standard biochemical and/or molecular identification methods. Minimum inhibitory concentrations were determined according to Clinical and Laboratory Standards Institute standards.
RESULTS: The most prevalent species was Haemophilus influenzae, followed by Staphylococcus epidermidis, Staphylococcus aureus, the Streptococcus mitis group, and Streptococcus pneumoniae. One species identified in this study, which was not previously noted as a common cause of bacterial conjunctivitis, was Dolosigranulum pigrum. Ampicillin resistance was common among H. influenzae isolates, while macrolide resistance was high among S. pneumoniae, S. epidermidis, and S. aureus. The latter two species also included a number of isolates resistant to methicillin and ciprofloxacin.
CONCLUSION: Antibiotic resistance among isolates remains a concern and the appearance of an emerging ocular pathogen, D. pigrum, suggests the need for continued observation. The topical ophthalmic fluoroquinolones continue to provide a good balance of low to moderate (i.e., manageable) levels of resistance plus broad-spectrum coverage for empiric treatment of ocular infections.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644963     DOI: 10.1007/s12325-012-0023-y

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  6 in total

1.  Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis.

Authors:  Jun-Jie Wang; Xin-Yi Gao; Hong-Zhuo Li; Shan-Shuang Du
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

2.  Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.

Authors:  Frank A Bucci; Ruth E Evans; Loretta M Amico; Timothy W Morris; Angel T Fluet; Christine M Sanfilippo; Heleen H DeCory; Timothy L Comstock
Journal:  Clin Ophthalmol       Date:  2015-05-13

3.  Unencapsulated Streptococcus pneumoniae from conjunctivitis encode variant traits and belong to a distinct phylogenetic cluster.

Authors:  Michael D Valentino; Abigail Manson McGuire; Jason W Rosch; Paulo J M Bispo; Corinna Burnham; Christine M Sanfilippo; Robert A Carter; Michael E Zegans; Bernard Beall; Ashlee M Earl; Elaine I Tuomanen; Timothy W Morris; Wolfgang Haas; Michael S Gilmore
Journal:  Nat Commun       Date:  2014-11-12       Impact factor: 14.919

4.  Dolosigranulum pigrum Cooperation and Competition in Human Nasal Microbiota.

Authors:  Silvio D Brugger; Sara M Eslami; Melinda M Pettigrew; Isabel F Escapa; Matthew T Henke; Yong Kong; Katherine P Lemon
Journal:  mSphere       Date:  2020-09-09       Impact factor: 4.389

5.  Population structure of ocular Streptococcus pneumoniae is highly diverse and formed by lineages that escape current vaccines.

Authors:  Camille Andre; John Rouhana; Suelen Scarpa de Mello; Gabriela Rosa da Cunha; Andrew G Van Camp; Michael S Gilmore; Paulo J M Bispo
Journal:  Microb Genom       Date:  2022-03

Review 6.  A Systematic Review of Multi-decade Antibiotic Resistance Data for Ocular Bacterial Pathogens in the United States.

Authors:  Paulo J M Bispo; Daniel F Sahm; Penny A Asbell
Journal:  Ophthalmol Ther       Date:  2022-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.